Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (831 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Three-dimensional biocompatible polymers in micrometer size range. They are typically spherical particles in a size range of 1-350 micrometers when used for drug delivery and 3D cell culture applications.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Microgel.
Where it fits in the MeSH classification
- Broader topics
- Polymers; Gels
Research landscape
PubMed indexes 813 records tagged with the MeSH heading “Microgels” (counts retrieved 2026-10-31). 769 of them (94.6%) were published from 2020 onward, and the busiest period so far is 2020 onward with 769 records.
Reviews account for 47 records (5.8%) and meta-analyses for 0. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 0 |
| 2000-2009 | 0 |
| 2010-2019 | 54 |
| 2020 onward | 769 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 47 | 5.8% |
| Meta-analyses | 0 | 0.0% |
| Randomized controlled trials | 0 | 0.0% |
Method: PubMed query "Microgels"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in drugs and chemicals
Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Microgel reinforced zwitterionic hydrogel coating for blood-contacting biomedical devices | 2022 | Research article Design not recorded in structured metadata | 166 | cc by PMID 36096894 · DOI · PMC9468150 |
| Microfluidic Formulation of Topological Hydrogels for Microtissue Engineering | 2022 | Review article Design not recorded in structured metadata | 89 | cc by PMID 36108106 · DOI · PMC9706502 |
| In situ 3D bioprinting with bioconcrete bioink | 2022 | Research article Design not recorded in structured metadata | 86 | cc by PMID 35739106 · DOI · PMC9225998 |
| Engineering osteoclast resorption units via sacrificial microgels in a bone-on-chip platform | 2026 | Research article Design not recorded in structured metadata | 5 | cc by PMID 41251267 · DOI · PMC12624845 |
Microgel reinforced zwitterionic hydrogel coating for blood-contacting biomedical devices [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Zwitterionic hydrogels exhibit eminent nonfouling and hemocompatibility.
- Closing excerpt
- This work provides new insights to guide the design of pure zwitterionic hydrogel coatings for biomedical devices.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (143 words)
Zwitterionic hydrogels exhibit eminent nonfouling and hemocompatibility. Several key challenges hinder their application as coating materials for blood-contacting biomedical devices, including weak mechanical strength and low adhesion to the substrate. Here, we report a poly(carboxybetaine) microgel reinforced poly(sulfobetaine) (pCBM/pSB) pure zwitterionic hydrogel with excellent mechanical robustness and anti-swelling properties. The pCBM/pSB hydrogel coating was bonded to the PVC substrate via the entanglement network between the pSB and PVC chain. Moreover, the pCBM/pSB hydrogel coating can maintain favorable stability even after 21 d PBS shearing, 0.5 h strong water flushing, 1000 underwater bends, and 100 sandpaper abrasions. Notably, the pCBM/pSB hydrogel coated PVC tubing can not only mitigate the foreign body response but also prevent thrombus formation ex vivo in rats and rabbits blood circulation without anticoagulants. This work provides new insights to guide the design of pure zwitterionic hydrogel coatings for biomedical devices.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36096894 · DOI · PMC9468150
Microfluidic Formulation of Topological Hydrogels for Microtissue Engineering [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Microfluidics has recently emerged as a powerful tool in generation of submillimeter-sized cell aggregates capable of performing tissue-specific functions, so-called microtissues, for applications in drug testing, regenerative medicine, and cell therapies.
- Closing excerpt
- Finally, we list the remaining challenges such as simplification of the microfluidic workflow for its widespread use in biomedical research, bench-to-bedside transition including production upscaling, further in vivo validation, generation of more precise organ-like models, as well as incorporation of induced pluripotent stem cells as a step toward clinical applications.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (264 words)
Microfluidics has recently emerged as a powerful tool in generation of submillimeter-sized cell aggregates capable of performing tissue-specific functions, so-called microtissues, for applications in drug testing, regenerative medicine, and cell therapies. In this work, we review the most recent advances in the field, with particular focus on the formulation of cell-encapsulating microgels of small "dimensionalities": "0D" (particles), "1D" (fibers), "2D" (sheets), etc., and with nontrivial internal topologies, typically consisting of multiple compartments loaded with different types of cells and/or biopolymers. Such structures, which we refer to as topological hydrogels or topological microgels (examples including core-shell or Janus microbeads and microfibers, hollow or porous microstructures, or granular hydrogels) can be precisely tailored with high reproducibility and throughput by using microfluidics and used to provide controlled "initial conditions" for cell proliferation and maturation into functional tissue-like microstructures. Microfluidic methods of formulation of topological biomaterials have enabled significant progress in engineering of miniature tissues and organs, such as pancreas, liver, muscle, bone, heart, neural tissue, or vasculature, as well as in fabrication of tailored microenvironments for stem-cell expansion and differentiation, or in cancer modeling, including generation of vascularized tumors for personalized drug testing. We review the available microfluidic fabrication methods by exploiting various cross-linking mechanisms and various routes toward compartmentalization and critically discuss the available tissue-specific applications. Finally, we list the remaining challenges such as simplification of the microfluidic workflow for its widespread use in biomedical research, bench-to-bedside transition including production upscaling, further in vivo validation, generation of more precise organ-like models, as well as incorporation of induced pluripotent stem cells as a step toward clinical applications.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36108106 · DOI · PMC9706502
In situ 3D bioprinting with bioconcrete bioink [3]
Abstract reading summary — source excerpts
- Opening excerpt
- In-situ bioprinting is attractive for directly depositing the therapy bioink at the defective organs to repair them, especially for occupations such as soldiers, athletes, and drivers who can be injured in emergency.
- Closing excerpt
- The cranial defects repair results verify the superiority of this bioink and its potential in clinical settings required in in-situ treatment.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (174 words)
In-situ bioprinting is attractive for directly depositing the therapy bioink at the defective organs to repair them, especially for occupations such as soldiers, athletes, and drivers who can be injured in emergency. However, traditional bioink displays obvious limitations in its complex operation environments. Here, we design a bioconcrete bioink with electrosprayed cell-laden microgels as the aggregate and gelatin methacryloyl (GelMA) precursor solution as the cement. Promising printability is guaranteed with a wide temperature range benefiting from robust rheological properties of photocrosslinked microgel aggregate and fluidity of GelMA cement. Composite components simultaneously self-adapt to biocompatibility and different tissue mechanical microenvironment. Strong binding on tissue-hydrogel interface is achieved by hydrogen bonds and friction when the cement is photocrosslinked. This bioink owns good portability and can be easily prepared in urgent accidents. Meanwhile, microgels can be cultured to mini tissues and then mixed as bioink aggregates, indicating our bioconcrete can be functionalized faster than normal bioinks. The cranial defects repair results verify the superiority of this bioink and its potential in clinical settings required in in-situ treatment.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 35739106 · DOI · PMC9225998
Engineering osteoclast resorption units via sacrificial microgels in a bone-on-chip platform [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Bone remodeling is a tightly regulated process essential for skeletal health, occurring within specialized structures known as bone multicellular units (BMUs).
- Closing excerpt
- It is thus a versatile tool for studying bone remodeling and has strong potential for application in disease modeling and drug screening for bone-related disorders.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (250 words)
Bone remodeling is a tightly regulated process essential for skeletal health, occurring within specialized structures known as bone multicellular units (BMUs). Despite extensive research, current animal models and conventional in vitro systems fail to reproduce the spatial and cellular complexity of human BMUs. Moreover, the mineralized nature of bone tissue poses imaging challenges due to its inherent opacity, limiting the ability to monitor osteoclast activity in complex 3D models. Control over the structure of in vitro BMU micro-confined niches would enable more effective 3D analysis readouts of osteoclast activity. Herein we developed a BMU-inspired bone-on-chip platform that enables localized, non-invasive analysis of human osteoclast function. Using microfluidic droplet generation, we encapsulated mature osteoclasts in monodisperse, enzymatically degradable dextran-tyramine (Dex-TA) microgels with defined size. These osteoclast-laden microgels were embedded within mineralized collagen hydrogels and selectively degraded to form confined, cell-populated microstructures directly on-chip. In addition, the contrast between the microcavities and surrounding mineralized matrix allowed non-destructive monitoring of matrix degradation using reflection confocal microscopy. Immunocytochemical analysis confirmed the morphological and functional differentiation of osteoclasts within the platform. Furthermore, our results demonstrated increased matrix resorption in response to RANKL treatment, validating the system's capacity to assess osteoclast activity under relevant stimuli. This bone-on-chip model overcomes key limitations of traditional systems by enabling spatial confinement, controlled degradation, and functional readouts of osteoclast behavior in a human-relevant 3D microenvironment. It is thus a versatile tool for studying bone remodeling and has strong potential for application in disease modeling and drug screening for bone-related disorders.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41251267 · DOI · PMC12624845
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article DNA Hydrogels and Microgels for Biosensing and Biomedical Applications [5]
- Research article Microgels: Modular, tunable constructs for tissue regeneration [6]
- Research article Recent Advances in Microgels: From Biomolecules to Functionality [7]
- Research article Translating Therapeutic Microgels into Clinical Applications [8]
- Research article Alginate microgels as delivery vehicles for cell-based therapies in tissue engineering and regenerative medicine [9]
- Research article Advances in the development of cyclodextrin-based nanogels/microgels for biomedical applications: Drug delivery and beyond [10]
References
- Yao M, Wei Z, Li J, Guo Z, Yan Z, Sun X, et al.. Microgel reinforced zwitterionic hydrogel coating for blood-contacting biomedical devices. . 2022. PMID 36096894 · DOI · PMC9468150
- Rojek KO, Ćwiklińska M, Kuczak J, Guzowski J. Microfluidic Formulation of Topological Hydrogels for Microtissue Engineering. . 2022. PMID 36108106 · DOI · PMC9706502
- Xie M, Shi Y, Zhang C, Ge M, Zhang J, Chen Z, et al.. In situ 3D bioprinting with bioconcrete bioink. . 2022. PMID 35739106 · DOI · PMC9225998
- Conceição F, Araújo-Gomes N, Husch JFA, Becker M, van den Beucken JJJP, Leijten J, et al.. Engineering osteoclast resorption units via sacrificial microgels in a bone-on-chip platform. . 2026. PMID 41251267 · DOI · PMC12624845
- Li F, Lyu D, Liu S, Guo W. DNA Hydrogels and Microgels for Biosensing and Biomedical Applications. Adv Mater. 2020. PMID 31379017 · DOI
- Newsom JP, Payne KA, Krebs MD. Microgels: Modular, tunable constructs for tissue regeneration. Acta Biomater. 2019. PMID 30769137 · DOI · PMC6441611
- Xu Y, Zhu H, Denduluri A, Ou Y, Erkamp NA, Qi R, et al.. Recent Advances in Microgels: From Biomolecules to Functionality. Small. 2022. PMID 35790106 · DOI
- Kittel Y, Kuehne AJC, De Laporte L. Translating Therapeutic Microgels into Clinical Applications. Adv Healthc Mater. 2022. PMID 34826201 · DOI
- Xu M, Qin M, Cheng Y, Niu X, Kong J, Zhang X, et al.. Alginate microgels as delivery vehicles for cell-based therapies in tissue engineering and regenerative medicine. Carbohydr Polym. 2021. PMID 34044944 · DOI
- Topuz F, Uyar T. Advances in the development of cyclodextrin-based nanogels/microgels for biomedical applications: Drug delivery and beyond. Carbohydr Polym. 2022. PMID 36184144 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.